DiaMedica Therapeutics Inc（DMAC）の株式分析DMACDiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

DiaMedica Therapeutics Inc (DMAC) is a good buy right now at a current price of $8.72, especially considering its recent 5-day change of +15.19% and an RSI of 67.548, indicating strong momentum. The stock has shown resilience with a 1-year change of +26.74%, suggesting a positive long-term trend. However, investors should be cautious of the widening net loss reported for Q2 2026, which reached -10.1 million USD, indicating ongoing financial challenges. Overall, the positive momentum and potential for recovery in clinical trials outweigh the risks, making DMAC a favorable investment opportunity.